Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 10/20 | 0.62 |
| ▸ | FAAH | O00519 | 5/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | XBP1 | P17861 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22398888 | 0.94 | PTGS1 (0.69) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL30180925 | 0.92 | PTGS1 (0.72) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL19817136 | 0.92 | PTGS1 (0.72) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL1887612 | 0.92 | PTGS1 (0.72) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL28698933 | 0.92 | PTGS1 (0.72) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL255340 | 0.89 | MGLL (0.52) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| Ethylene Glycol SCHEMBL2193141 | 0.83 | PTGS1 (0.47) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| Ethylene Glycol SCHEMBL1082278 | 0.83 | PTGS1 (0.47) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL155346 | 0.83 | PTGS1 (0.85) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL1965501 | 0.83 | MGLL (0.62) | MGLLFAAHPTGS1PTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737251-B2 | Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders | CONJUCHEM BIOTECHNOLOGIES INC. (CA) | 2010-06-15 | — | — | US | claimed |
| EP-2114437-A2 | MODIFIED CORTICOTROPIN RELEASING FACTOR PEPTIDES AND USES THEREOF | ConjuChem Biotechnologies Inc. (CA) | 2009-11-11 | — | — | EP | claimed |
| US-20090054332-A1 | THOMBOPOIETIN PEPTIDE CONJUGATES | CONJUCHEM BIOTECHNOLOGIES, INC. (CA) | 2009-02-26 | — | — | US | claimed |
| WO-2008157824-A2 | THROMBOPOIETIN PEPTIDE CONJUGATES | CONJUCHEM BIOTECHNOLOGIES INC. (CA) | 2008-12-24 | — | — | WO | claimed |
| CN-101289500-A | Long lasting fusion peptide inhibitor of viral infection | CONJUCHEM BIOTECHNOLOGIES INC (CA) | 2008-10-22 | — | — | CN | claimed |
| EP-1980572-A1 | Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders | ConjuChem Biotechnologies Inc. (CA) | 2008-10-15 | — | — | EP | claimed |
| US-20080167231-A1 | Modified Corticotropin Releasing Factor Peptides and Uses Thereof | CONJUCHEM BIOTECHNOLOGIES INC. | 2008-07-10 | — | — | US | claimed |
| WO-2008047241-A2 | MODIFIED CORTICOTROPIN RELEASING FACTOR PEPTIDES AND USES THEREOF | CONJUCHEM BIOTECHNOLOGIES INC. (US) | 2008-04-24 | — | — | WO | claimed |
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | ALPHA 9 ONCOLOGY INC (CA) | 2026-03-19 | — | — | US | disclosed |
| US-20250195702-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-06-19 | — | — | US | disclosed |
| US-20250186627-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-06-12 | — | — | US | disclosed |
| US-20250161501-A1 | Radiolabeled Compounds for Imaging of Fibroblast Activation Protein (FAP) and Treatment of FAP-Related Disorders | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-05-22 | — | — | US | disclosed |
| WO-2025054727-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-03-20 | — | — | WO | disclosed |
| US-12246076-B2 | Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-03-11 | — | — | US | disclosed |
| WO-2003005026-A2 | CHEMICAL CAPTURE REAGENT | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2003-01-16 | — | — | WO | disclosed |
| WO-2002066511-A2 | LONG LASTING GLUCAGON-LIKE PEPTIDE 2 (GLP-2) FOR THE TREATMENT OF GASTROINTESTINAL DISEASES AND DISORDERS | CONJUCHEM INC. (CA) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002062844-A2 | LONG LASTING GROWTH HORMONE RELEASING FACTOR DERIVATIVES | CONJUCHEM INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| CN-1351611-A | Long-acting Fusion Peptide Inhibitors of Viral Infection | CONJUCHEM INC (CA) | 2002-05-29 | — | — | CN | disclosed |
| EP-1042003-A1 | DELIVERY OF LONG LASTING THERAPEUTIC AGENTS BY FORMING COVALENT ATTACHMENTS IN VIVO | Conjuchem, Inc. (CA) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999048536-A2 | DELIVERY OF LONG LASTING THERAPEUTIC AGENTS BY FORMING COVALENT ATTACHMENTS IN VIVO | CONJUCHEM, INC. (CA) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186627-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | FSHR, ESRRA, ESRRG | MGLL 4201/4885FAAH 3570/4885PTGS1 4532/4885 |
| US-20250161501-A1 | Radiolabeled Compounds for Imaging of Fibroblast Activation Protein (FAP) and Treatment of FAP-Related Disorders | FAP, FIBP, FGFR1 | MGLL 3061/4885FAAH 39/4885PTGS1 3440/4885 |
| US-12246076-B2 | Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders | GRPR, NPY5R, NPY2R | MGLL 3505/4885FAAH 814/4885PTGS1 2081/4885 |
| US-20250195702-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | GRPR, NPY5R, NPY2R | MGLL 3330/4885FAAH 636/4885PTGS1 2040/4885 |
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | GRPR, GIPR, GLP1R | MGLL 1847/4885FAAH 874/4885PTGS1 1358/4885 |
| US-20090054332-A1 | THOMBOPOIETIN PEPTIDE CONJUGATES | TEK, MPL, PTMS | MGLL 4269/4885FAAH 2922/4885PTGS1 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.